KDR and neoplasm: Anlotinib is an oral tyrosine kinase inhibitor that can effectively inhibit the kinases of vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), stem cell factor receptor (c-Kit), etc. Anlotinib has the potential to be an anti-kinase and has the ability to inhibit the kinases of FGFR and c-Kit, which have dual roles of anti-tumor angiogenesis and tumor growth inhibition (21–23).